Piper Sandler Increases Hims & Hers Health (NYSE:HIMS) Price Target to $35.00

Hims & Hers Health (NYSE:HIMS) had its price target increased by equities research analysts at Piper Sandler from $24.00 to $35.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Piper Sandler’s price objective would indicate a potential downside of 12.64% from the stock’s previous close.

Other analysts have also recently issued research reports about the company. Bank of America increased their target price on Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a research report on Thursday, February 20th. BTIG Research started coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price on the stock. TD Cowen reissued a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Citigroup lifted their price objective on shares of Hims & Hers Health from $25.00 to $27.00 and gave the stock a “sell” rating in a research report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $31.40.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $40.06 on Tuesday. Hims & Hers Health has a 1 year low of $9.67 and a 1 year high of $72.98. The business has a 50 day simple moving average of $35.45 and a two-hundred day simple moving average of $26.08. The firm has a market capitalization of $8.75 billion, a PE ratio of 90.55 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $470.50 million. Equities research analysts expect that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 4,152 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now directly owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29. Following the transaction, the chief executive officer now owns 97,687 shares of the company’s stock, valued at $5,692,221.49. The trade was a 56.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,080,275 shares of company stock valued at $37,247,354 over the last quarter. 17.71% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. SlateStone Wealth LLC lifted its stake in shares of Hims & Hers Health by 4.0% in the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after purchasing an additional 413 shares during the period. Blume Capital Management Inc. increased its holdings in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 600 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in Hims & Hers Health by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock valued at $480,000 after buying an additional 628 shares in the last quarter. Quest Partners LLC raised its position in shares of Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after acquiring an additional 807 shares during the period. Finally, Harbour Investments Inc. boosted its stake in shares of Hims & Hers Health by 18.8% during the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock worth $127,000 after acquiring an additional 833 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.